Erratum to: VEGF as a paracrine regulator of conventional outflow Facility (Invest Ophthalmol Vis Sci., (2017), 58, (1899-1908), 10.1167/iovs.16-20779);VEGF as a paracrine regulator of conventional outflow facility

Investigative Ophthalmology and Visual Science

Volumn 58, Issue 3, 2017, Pages 1899-1908

  Reina Torres, Ester ^a   Wen, Joanne C ^b,d   Liu, Katy C ^b   Li, Guorong ^b   Sherwood, Joseph M ^a   Chang, Jason Y H ^a   Challa, Pratap ^b   Flügel Koch, Cassandra M ^c   Stamer, W Daniel ^b   Allingham, R Rand ^b   Overby, Darryl R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Mouse models; Outflow facility; Schlemm s canal; Trabecular meshwork; Vascular endothelial growth factor

Indexed keywords

KI 8751; POLYCLONAL ANTIBODY; RANIBIZUMAB; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR OUTFLOW; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MECHANICAL STRESS; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHLEMM CANAL; TRABECULAR MESHWORK; ANIMAL; ANIMAL MODEL; AQUEOUS HUMOR; C57BL MOUSE; CELL CULTURE; CYTOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; AQUEOUS HUMOR; CELLS, CULTURED; HUMANS; INTRAOCULAR PRESSURE; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OCULAR HYPERTENSION; TRABECULAR MESHWORK; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85016623735     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-20779a     Document Type: Erratum

References (95)

1. Grant WM. Clinical measurements of aqueous outflow. Am J Ophthalmol. 1951;34:1603–1605.
2. Lütjen-Drecoll E. Structural factors influencing outflow facility and its changeability under drugs. A study in Macaca arctoides. Invest Ophthalmol Vis Sci. 1973;12:280–294.
3. Mäepea O, Bill A. Pressures in the juxtacanalicular tissue and Schlemm’s canal in monkeys. Exp Eye Res. 1992;54:879–883.
4. Holmberg A. The fine structure of the inner wall of Schlemm’s canal. AMA Arch Ophthalmol. 1959;62:956–958.
5. Inomata H, Smelser GK, Bill A. Aqueous humor pathways through trabecular meshwork and into Schlemm’s canal in cynomolgus monkey (Macaca Irus). Am J Ophthalmol. 1972; 73:760–790.
6. Grierson I, Lee WR, Moseley H, Abraham S. The trabecular wall of Schlemm’s canal: a study of the effects of pilocarpine by scanning electron microscopy. Br J Ophthalmol. 1979;63: 9–16.
7. Ethier CR, Coloma FM, Sit AJ, Johnson M. Two pore types in the inner-wall endothelium of Schlemm’s canal. Invest Ophthalmol Vis Sci. 1998;39:2041–2048.
8. Braakman ST, Read AT, Chan DW, Ethier CR, Overby DR. Colocalization of outflow segmentation and pores along the inner wall of Schlemm’s canal. Exp Eye Res. 2015;130:87–96.
9. Allingham RR, Dekater AW, Ethier CR, et al. The relationship between pore density and outflow facility in human eyes. Invest Ophthalmol Vis Sci. 1992;33:1661–1669.
10. Johnson M, Chan D, Reed AT, et al. The pore density in the inner wall endothelium of Schlemm’s canal of glaucomatous eyes. Invest Ophthalmol Vis Sci. 2002;43:2950–2955.
11. Overby DR, Zhou EH, Vargas-Pinto R, et al. Altered mechanobiology of Schlemm’s canal endothelial cells in glaucoma. Proc Natl Acad Sci U S A. 2014;111:13876–13881.
12. Johnson M, Shapiro A, Ethier CR, Kamm RD. Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci. 1992;33:1670–1675.
13. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50:1774–1778.
14. Esser S, Wolburg K, Wolburg H, et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998;140:947–959.
15. Satchell SC, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 2009;296:F947–F956.
16. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223–1234.
17. Monaghan-Benson E, Burridge K. The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species. J Biol Chem. 2009; 284:25602–25611.
18. Fuchshofer R, Stephan DA, Russell P, Tamm ER. Gene expression profiling of TGFbeta2- and/or BMP7-treated trabecular meshwork cells: identification of Smad7 as a critical inhibitor of TGF-beta2 signaling. Exp Eye Res. 2009; 88:1020–1032.
19. Fujimoto T, Inoue T, Maki K, Inoue-Mochita M, Tanihara H. Vascular endothelial growth factor-A increases the aqueous humor outflow facility. PLoS One. 2016;11:e0161332.
20. Ramos RF, Hoying JB, Witte MH, Stamer WD. Schlemm’s canal endothelia, lymphatic, or blood vasculature? J Glaucoma. 2007;16:391–405.
21. Perkumas KM, Stamer WD. Protein markers and differentiation in culture for Schlemm’s canal endothelial cells. Exp Eye Res. 2012;96:82–87.
22. Sano K, Katsuta O, Shirae S, et al. Flt1 and Flk1 mediate regulation of intraocular pressure and their double heterozygosity causes the buphthalmia in mice. Biochem Biophys Res Commun. 2012;420:422–427.
23. Karpinich NO, Caron KM. Schlemm’s canal: more than meets the eye, lymphatics in disguise. J Clin Invest. 2014;124:3701–3703.
24. Kizhatil K, Ryan M, Marchant JK, Henrich S, John SW. Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process. PLoS Biol. 2014;12:e1001912.
25. Aspelund A, Tammela T, Antila S, et al. The Schlemm’s canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. J Clin Invest. 2014;124:3975–3986.
26. Rogers ME, Navarro ID, Perkumas KM, et al. Pigment epithelium-derived factor decreases outflow facility. Invest Ophthalmol Vis Sci. 2013;54:6655–6661.
27. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010;4:28–29.
28. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111–1114.
29. Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119:321–326.
30. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013; 33:179–187.
31. Loukianou E, Brouzas D, Apostolopoulos M. Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab. Int Ophthalmol. 2011;31:211–213.
32. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250:1435–1440.
33. Segal O, Ferencz JR, Cohen P, Nemet AY, Nesher R. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Isr Med Assoc J. 2013;15:352–355.
34. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma. 2010;19:437–441.
35. Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52:1023–1034.
36. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158:319–327.
37. Wen JC, Reina-Torres E, Sherwood JM, et al. Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:1893–1898.
38. Smith RS, Zabaleta A, Savinova OV, John SW. The mouse anterior chamber angle and trabecular meshwork develop without cell death. BMC Dev Biol. 2001;1:3.
39. Overby DR, Bertrand J, Schicht M, et al. The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice. Invest Ophthalmol Vis Sci. 2014;55:3727–3736.
40. Millar JC, Clark AF, Pang IH. Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion. Invest Ophthalmol Vis Sci. 2011;52:685–694.
41. Boussommier-Calleja A, Bertrand J, Woodward DF, et al. Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. Invest Ophthalmol Vis Sci. 2012;53: 5838–5845.
42. Overby DR, Bertrand J, Tektas OY, et al. Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice. Invest Ophthalmol Vis Sci. 2014;55: 4922–4933.
43. Li G, Farsiu S, Chiu SJ, et al. Pilocarpine-induced dilation of Schlemm’s canal and prevention of lumen collapse at elevated intraocular pressures in living mice visualized by OCT. Invest Ophthalmol Vis Sci. 2014;55:3737–3746.
44. Li P, Shen TT, Johnstone M, Wang RK. Pulsatile motion of the trabecular meshwork in healthy human subjects quantified by phase-sensitive optical coherence tomography. Biomed Opt Express. 2013;4:2051–2065.
45. Sherwood JM, Reina-Torres E, Bertrand JA, Rowe B, Overby DR. Measurement of outflow facility using iPerfusion. PLoS One. 2016;11:e0150694.
46. 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123–4131.
47. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14:611–617.
48. Coleman DJ, Trokel S. Direct-recorded intraocular pressure variations in a human subject. Arch Ophthalmol. 1969;82: 637–640.
49. Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52:2147–2152.
50. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676.
51. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99–106.
52. Itokawa T, Nokihara H, Nishioka Y, et al. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther. 2002;1:295–302.
53. Tille JC, Wang X, Lipson KE, et al. Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaN-deltaC)-and VEGF-A-induced angiogenesis in vitro. Exp Cell Res. 2003;285:286–298.
54. ʹ -{4-(4-quinolyloxy)phenyl}ureas. J MedChem. 2005; 48:1359–1366.
55. 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822–7835.
56. 165b in podocytes reduces glomerular permeability. J Am Soc Nephrol. 2010;21:1498–1509.
57. 165b in pathophysiology. Cell Adh Migr. 2012;6:561–568.
58. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548–553.
59. Achen MG, Stacker SA. The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int J Exp Pathol. 1998;79:255–265.
60. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008;49:522–527.
61. Miki K, Miki A, Matsuoka M, et al. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology. 2009;116:1748–1754.
62. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369–2379.
63. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 1992;114:521–532.
64. Ford KM, Saint-Geniez M, Walshe TE, D’Amore PA. Expression and role of VEGF-A in the ciliary body. Invest Ophthalmol Vis Sci. 2012;53:7520–7527.
65. Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res. 2009;88: 648–655.
66. Hillman NJ, Whittles CE, Pocock TM, Williams B, Bates DO. Differential effects of vascular endothelial growth factor-C and placental growth factor-1 on the hydraulic conductivity of frog mesenteric capillaries. J Vasc Res. 2001;38:176–186.
67. Whittles CE, Pocock TM, Wedge SR, et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation. 2002;9:513–522.
68. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol. 1999;10:528–535.
69. Hamanaka T, Bill A, Ichinohasama R, Ishida T. Aspects of the development of Schlemm’s canal. Exp Eye Res. 1992;55:479–488.
70. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611–625.
71. Karnezis T, Shayan R, Caesar C, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell. 2012;21:181–195.
72. Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30:102–109.
73. Millard LH, Woodward DF, Stamer WD. The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci. 2011;52:3506–3513.
74. Kim YW, Byzova TV. Oxidative stress in angiogenesis and vascular disease. Blood. 2014;123:625–631.
75. Galvagni F, Pennacchini S, Salameh A, et al. Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. Circ Res. 2010;106:1839–1848.
76. Downs JC, Burgoyne CF, Seigfreid WP, et al. 24-hour IOP telemetry in the nonhuman primate: implant system performance and initial characterization of IOP at multiple timescales. Invest Ophthalmol Vis Sci. 2011;52:7365–7375.
77. Rohen JW, Futa R, Lütjen-Drecoll E. The fine-structure of the cribriform meshwork in normal and glaucomatous eyes as seen in tangential sections. Invest Ophthalmol Vis Sci. 1981; 21:574–585.
78. Bradley JM, Kelley MJ, Zhu X, et al. Effects of mechanical stretching on trabecular matrix metalloproteinases. Invest Ophthalmol Vis Sci. 2001;42:1505–1513.
79. Li A, Leung CT, Peterson-Yantorno K, Stamer WD, Civan MM. Cytoskeletal dependence of adenosine triphosphate release by human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52:7996–8005.
80. Tripathi RC, Li JP, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–237.
81. Hu DN, Ritch R, Liebmann J, et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406–410.
82. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141: 456–462.
83. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125:1363–1366.
84. Roh MI, Kim HS, Song JH, et al. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Retina. 2009;29:523–529.
85. Takai Y, Tanito M, Ohira A. Multiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract. Invest Ophthalmol Vis Sci. 2012;53:241–247.
86. Costagliola C, Daniele A, dell’Omo R, et al. Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. Exp Eye Res. 2013;110:50–54.
87. Hsu MY, Yang CY, Hsu WH, et al. Monitoring the VEGF level in aqueous humor of patients with ophthalmologically relevant diseases via ultrahigh sensitive paper-based ELISA. Biomaterials. 2014;35:3729–3735.
88. Wang JW, Zhou MW, Zhang X, et al. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma. Clin Experiment Ophthalmol. 2015;43:415–421.
89. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem. 2002;277:50081–50086.
90. Wu WK, Llewellyn OP, Bates DO, Nicholson LB, Dick AD. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology. 2010;215:796–803.
91. McMenamin PG, Holthouse I. Immunohistochemical characterization of dendritic cells and macrophages in the aqueous outflow pathways of the rat eye. Exp Eye Res. 1992;55:315–324.
92. Flügel C, Kinne RW, Streilein JW, Lütjen-Drecoll E. Distinctive distribution of HLA class II presenting and bone marrow derived cells in the anterior segment of human eyes. Curr Eye Res. 1992;11:1173–1183.
93. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011;31:1028–1035.
94. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30:887–892.
95. Gal-Or O, Dotan A, Dachbash M, et al. Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. Exp Eye Res. 2016;145:412–416.